MedTrace Logo

Pilot Trial of Naltrexone for Obesity in Women With Schizophrenia

NCT00793780 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-10-06

Study results available
· View outcomes & findings →

Summary

The purpose of this clinical trial is to find out how effective low dose oral naltrexone is on reducing body weight when compared to placebo in women with schizophrenia and schizoaffective disorder.

Conditions

Interventions

DRUG

Naltrexone 25mg

Naltrexone 25mg caplets taken orally once a day for 8 weeks

OTHER

Placebo

Placebo caplet (inactive substance) taken orally once a day for 8 weeks

Sponsors & Collaborators

  • Ethel F. Donaghue Women's Health Investigator Program at Yale

    collaborator UNKNOWN

  • Yale University

    lead OTHER

Principal Investigators

  • Cenk Tek, M.D. · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00793780 on ClinicalTrials.gov